Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.47 |
| ▸ | STS | P08842 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3129522 | 1.00 | ALDH1A1 (0.54) | ALDH1A1LMNAMAPTGPR119STS | |
| SCHEMBL3127065 | 0.94 | ALDH1A1 (0.52) | ALDH1A1LMNAMAPTGPR119STS | |
| SCHEMBL26091331 | 0.93 | ALDH1A1 (0.59) | ALDH1A1LMNAMAPTGPR119STS | |
| SCHEMBL27844213 | 0.89 | ALDH1A1 (0.55) | ALDH1A1LMNAMAPTGPR119STS | |
| SCHEMBL2683671 | 0.89 | ALOX5 (0.48) | ALDH1A1LMNAMAPTGPR119STS | |
| SCHEMBL2683675 | 0.89 | ALOX5 (0.48) | ALDH1A1LMNAMAPTGPR119STS | |
| SCHEMBL23250075 | 0.88 | GPR119 (0.54) | ALDH1A1LMNAMAPTGPR119STS | |
| SCHEMBL221064 | 0.86 | CYP2D6 (0.54) | GPR119STS | |
| SCHEMBL222877 | 0.86 | CYP2D6 (0.54) | GPR119STS | |
| SCHEMBL221063 | 0.86 | CYP2D6 (0.54) | GPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ERBB2, ERBB4, EGFR | ALDH1A1 2461/4885LMNA 2256/4885MAPT 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.